RxDoctor Payments Data

Sean Sider, DPM

Foot & Ankle Surgery · Baltimore, MDNPI 1215054994

Payments from drug & device makers

$1,294in general payments, 2019–2025

Across 36 payments — averaging $35.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$397
  • Smith+Nephew$165
  • Collaborative Care Diagnostics, LLC$135
  • Aroa Biosurgery Incorporated$129
  • Stryker$122
  • Nevro Corp.$91
  • plus $255 from 9 others

What the payments were for

  • Food & beverage$1,25097%
  • Education$443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,294 in reported general payments places this provider in the 35th percentile of 182 foot & ankle surgery providers in Maryland.

See all foot & ankle surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$272,491
Medicare patients
658
Services billed
4,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole34$39,318
Naftifine Hcl34$8,180
Tavaborole15$2,741
Pregabalin43$1,894
Gabapentin61$1,604
Celecoxib44$1,296
CiclopiroxCiclopirox Olamine49$1,178
Diclofenac Sodium20$812
Terbinafine Hcl34$607
Clobetasol Propionate19$580
Triamcinolone Acetonide81$555
Diclofenac Potassium30$512
Meloxicam34$422
Silver Sulfadiazine23$206
Doxycycline Hyclate19$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$12$39,31834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 182 foot & ankle surgery providers in Maryland.

Other foot & ankle surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →